The legal back and forth between Dexcom (NSDQ:DXCM) and AgaMatrix over the companies’ continuous glucose monitoring IP dates back to March of 2016, when AgaMatrix launched a patent infringement lawsuit against the San Diego, Calif.-based manufacturer in the U.S. District Court of Oregon.
Later that year, Dexcom filed for inter parters review with the Patent Trial and Appeal Board, hoping that the board would find that the patents cited in AgaMatrix’s lawsuit were invalid under patent law. But today, the PTAB ruled that AgaMatrix’s patents are valid and that Dexcom failed to prove that the claims were unpatentable due to obviousness.
The Oregon lawsuit was previously stayed, pending the board’s inter partes review.
This is not the only time the two companies have battled over IP in court. In Aug. 2015, Dexcom shot back at AgaMatrix and filed a patent infringement suit in the U.S. Central District Court of California. The judge ruled this year that AgaMatrix’s product does not infringe upon Dexcom’s patent, according to Dexcom’s annual report.
The CGM-maker has filed a patent infringement suit against AgaMatrix in the U.S. District Court of Delaware, alleging that AgaMatrix’s single-point blood glucose monitoring product infringes upon two patents held by Dexcom.
Are the specifics of the patent known?